Abstract
Thrombotic thrombocytopenic purpura (TTP) is a well-described complication of systemic lupus erythematosus (SLE).1 Historically, plasma exchange has been the mainstay of treatment for TTP as well as for other thrombotic microangiopathies.2 Recently, the complement inhibitor eculizumab has demonstrated efficacy in treating atypical hemolytic uremic syndrome (aHUS).3 Whether eculizumab therapy could be beneficial in the treatment of TTP is unknown. We report a case of pediatric SLE-associated TTP treated with eculizumab, in conjunction with steroids, plasma exchange, and additional immunosuppressant therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.